NEW YORK, Dec. 5 - Lyle Turner, the gregarious founder, CEO, and chairman of Invitrogen, will step down at the end of the year, the company said today.
James Glynn, Invitrogen's executive vice president and former CFO, has been named president and COO. When Turner leaves Jan. 1, Glynn will assume the role of interim CEO until a permanent chief is hired. Bradley Lorimier, a current board member, will become chairman.
Invitrogen said it hopes to have a new CEO in place before the end of June, though the company said it has no specific timeline.